A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK-1084 and if people tolerate it when taken with other treatments * How many people have the cancer respond (get smaller or go away) to the treatments

Trial Details

NCT ID

NCT07286149

Phase

PHASE1 / PHASE2

Sponsor

Merck Sharp & Dohme LLC

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

MK-1084
Patritumab deruxtecan
Sacituzumab tirumotecan
Cetuximab
Rescue Medications

Locations (sample)

Clermont, Florida, United States|28.54944,-81.77285
Chicago, Illinois, United States|41.85003,-87.65005
Portland, Oregon, United States|45.52345,-122.67621
Portland, Oregon, United States|45.52345,-122.67621
Barretos, São Paulo, Brazil|-20.55722,-48.56778

Key Eligibility Criteria

The main inclusion criteria include but are not limited to the following:
Has histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)
Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene (KRAS) mut…
Has documented disease progression after receiving 1-2 prior lines of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) ther…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →